Nivolumab in advanced lung cancer: Indication of major added benefit

August 18, 2016, Institute for Quality and Efficiency in Health Care

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether in these patients this monoclonal antibody offers advantages over the appropriate comparator therapy.

According to the findings, there is an indication of a major added benefit of nivolumab over docetaxel. An added benefit over the appropriate comparator therapy (best supportive care) is not proven in patients for whom treatment with docetaxel or similar drugs is not indicated.

Approval study stopped early due to survival advantage

The Federal Joint Committee (G-BA) specified docetaxel, pemetrexed or - depending on the mutation status - gefitinib, erlotinib or crizotinib as the appropriate comparator therapy. Patients for whom these drugs are not indicated were to be treated in the control arm with best supportive care instead, that is, treatment tailored to the individual patient's needs in order to alleviate pain and improve quality of life. The manufacturer did not present data on this second research question.

For the first research question, the manufacturer cited the approval study CA209-057, in which nivolumab was compared with docetaxel. After an interim analysis, all patients in the docetaxel arm were offered the option of further treatment with nivolumab, as the new drug showed clear advantages for overall survival. However, only PD-L1-positive patients had a statistically significant . In contrast, an added benefit for overall survival is not proven in patients with a negative PD-L1 status.

Also advantages for side effects

Nivolumab also has advantages over docetaxel with regard to several outcomes from the category "side effects" (severe and serious adverse events, discontinuation due to adverse events, alopecia, and blood and lymphatic system disorders).

Overall, for patients who can be treated with and similar drugs the data provide an indication of a major added benefit of nivolumab over the appropriate . Due to a lack of data, an added benefit is not proven for for whom such drugs are not indicated.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the Federal Joint Committee (G-BA). After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.

An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the Website gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language information.

More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on informedhealth.org).

Explore further: Afatinib in advanced squamous cell carcinoma of the lung: Added benefit not proven

More information: www.iqwig.de/download/A16-25_N … ertung-35a-SGB-V.pdf

Related Stories

Afatinib in advanced squamous cell carcinoma of the lung: Added benefit not proven

August 18, 2016
Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. ...

Nivolumab in renal cell cancer: Indication of added benefit

August 10, 2016
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. In an early benefit assessment, the German Institute ...

Ramucirumab in stomach cancer: Added benefit not proven

August 18, 2016
Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. This aims to slow the growth of the tumours. As a so-called ...

Nivolumab in NSCLC: Indication of major added benefit for under 75-year-olds

November 18, 2015
Nivolumab is an anti-tumour drug from the group of monoclonal antibodies. It has been available since June 2015 under the trade name Opdivo for adults with advanced melanoma, and since July 2015 under the trade name Nivolumab ...

Ramucirumab in colorectal and lung cancer: Partly added benefit, partly lesser benefit

June 3, 2016
Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. This aims to slow the growth of the tumours. The German ...

Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven

August 18, 2016
The drug combination emtricitabine/tenofovir alafenamide is approved in combination with other antiviral agents for the treatment of adults and adolescents infected with human immunodeficiency virus type 1 (HIV-1). In an ...

Recommended for you

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

Prescription drug monitoring programs may have negative unintended consequences

May 7, 2018
Prescription drug monitoring programs (PDMPs) are a key component of the President's Prescription Drug Abuse Prevention Plan and considered a critical tool for reducing prescription opioid-related illness and death. The results ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.